Related Experiment Videos
Basophils and eosinophils in allergic rhinitis
R M Naclerio1, F M Baroody, A Kagey-Sobotka
1Department of Medicine (Division of Clinical Immunology), Johns Hopkins University School of Medicine, Baltimore, Md.
The Journal of Allergy and Clinical Immunology
|December 1, 1994
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
The EUFOREA pocket guide for chronic rhinosinusitis.
Rhinology·2022
Hot, humid air increases cellular influx during the late-phase response to nasal challenge with antigen.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2001
The nasal passage of subjects with asthma has a decreased ability to warm and humidify inspired air.
American journal of respiratory and critical care medicine·2001
TNF-alpha is a master regulator of drug-specific T-cell activation.
The Journal of allergy and clinical immunology·2026
Decoding the epithelial-stromal interactome in allergic rhinitis through single-cell multi-omics integration.
The Journal of allergy and clinical immunology·2026
IgE-Sensitized Mast Cells Release Extracellular Vesicles that Transfer IgE and Spread Allergic Sensitization.
The Journal of allergy and clinical immunology·2026
Post-GWAS Variant-to-Function Challenges in Asthma Research.
The Journal of allergy and clinical immunology·2026
AMPK-driven immunometabolic reprogramming enhances CD19<sup>+</sup>CD21<sup>hi</sup>CD24<sup>hi</sup> regulatory B cell-mediated suppression of atopic dermatitis.
The Journal of allergy and clinical immunology·2026
Comparative Efficacy of Biologic Agents for Severe Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and Network Meta-analysis.
The Journal of allergy and clinical immunology·2026
Upadacitinib for refractory generalized lichen sclerosus: a case report and brief literature review.
Frontiers in immunology·2026
Case Report: A case report of bullous pemphigoid triggered by sintilimab (PD-1 inhibitor).
Frontiers in immunology·2026